) as his top pick, believing that its drugs in development are promising. He specifically highlights ELVN-001, which is for a type of blood cancer called CML. He explains,"What you would want with these particular products is that they don't have any sort of cardiovascular toxicity, and they just put out six-month or 24-week safety data, and it looked pretty clean."
Efficacy and safety look good now just to take a step back in Life is an experimental stage pharmaceutical company, so it doesn't have any drugs on the market, right?It's for type of blood cancer called CML.And it's also looks pretty good in terms of safety. We think it's pretty feasible that a product like in live in 01, even when you're talking about not getting they call it first line share.But even the second drug after the first line, right?
Um, the the that people are looking at right now in terms of launch and sort of as an analogue for what this market could be with a cleaner TK.Now this one is very solid.The stock is up this year, it's up about 17%.When when you talk to the biotech specialist community, it's very difficult for folks to get to a DC F valuation where the stock is train.
And you may not know exactly what is Does that mean like the you know, the the you know, the the P MS of the generals P MS in the market.That's the question that I think people well, it's not good enough for you to have it as a buy right now.And thank you so much for watching goodbye or goodbye.Chelsea cannot rely on Cole Palmer to solve all problems – Enzo MarescaTesla kicks off the earnings season for Magnificent Seven tech names next week.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Herkunft: globeandmail - 🏆 5. / 92 Weiterlesen »